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Abstract
Introduction: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for
treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies. This approval was
based on evidence from FAME trials which were conducted at a time when ranibizumab was not available. There is a
paucity of data on implementation of guidance on selecting patients for this treatment modality and also on the real
world outcome of fluocinolone therapy especially in those patients that have been unresponsive to ranibizumab therapy.
Method: Retrospective study of consecutive patients treated with fluocinolone between January and August 2014 at
three sites were included to evaluate selection criteria used, baseline characteristics and clinical outcomes at
3-month time point.
Results: Twenty two pseudophakic eyes of 22 consecutive patients were included. Majority of patients had prior therapy
with multiple intravitreal anti-VEGF injections. Four eyes had controlled glaucoma. At baseline mean VA and CRT were
50.7 letters and 631 μm respectively. After 3 months, 18 patients had improved CRT of which 15 of them also had
improved VA. No adverse effects were noted. One additional patient required IOP lowering medication. Despite being
unresponsive to multiple prior therapies including laser and anti-VEGF injections, switching to fluocinolone achieved
treatment benefit.
Conclusion: The patient level selection criteria proposed by NICE guidance on fluocinolone appeared to be
implemented. This data from this study provides new evidence on early outcomes following fluocinolone therapy in eyes
with DMO which had not responded to laser and other intravitreal agents.
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Background
Diabetic Macular Oedema (DMO) is one of the leading
causes of blindness in the working-age population [1, 2]
In the UK, 17.7 % of severe sight impairment certifica-
tions in adults aged 16–64 has been attributed to dia-
betes [3]. Several landmark clinical trials have
established the firm position of intravitreal anti-VEGF
agents as the first line therapy of choice for DMO [4–6].
Intravitreal corticosteroids have also been shown to be
effective in achieving visual gain and reduction of
oedema in DMO and with reduced frequency of injec-
tions needed [7–9], but with associated risks of causing
steroid induced cataract or ocular hypertension and
glaucoma. Current guidelines therefore, recommend
their use only in those eyes which have either chronic
oedema not responsive to laser or those eyes with
oedema that have not responded to repeated injections
of anti-VEGF agents [10, 11].
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There are currently three corticosteroid agents that
have been used for DMO; triamcinolone [7], fluocino-
lone implant releasing 0.2 μg/day of fluocinolone aceto-
nide (ILUVIEN®, Alimera Sciences Limited, Aldershot,
UK) [8] and dexamethasone implant containing 700 μg
of dexamethasone (Ozurdex®, Allergan, Inc., Irvine, CA,
USA) [9]. The United Kingdom was one of the first
countries to approve the use fluocinolone implant for
treatment of DMO but current National Institute for
Care and Health Excellence (NICE) guidance recom-
mends its use only in pseudophakic eyes with DMO that
has been unresponsive to other available therapy [10].
Due to this unique selection criteria and early exposure
to this technology, the setting in our National Health
Service in the United Kingdom is therefore ideal for
reporting the implementation of this guidance, in par-
ticular, the early experiences in patient selection behav-
iour by clinicians and also early clinical outcomes in the
real world. Such data may be useful for developing fu-
ture strategies for reducing the frequency of side effects,
design of follow-up regimen that can further justify the
use of such a unique treatment with its prolonged dur-
ation of action.
This retrospective study reports the initial real world
experience of implementation of TA301 in the clinical
setting, in particular, the patient level criteria used for
selection of patients for intravitreal fluocinolone implant,
the initial treatment response and the short term safety
profile.
Methods
Consecutive patients treated at each of three hospital de-
partments using fluocinolone implant for DMO accord-
ing to NICE guidance (TA301) between January 2014
and August 2014 were identified at each site using their
respective patient database systems for tracking patients
on intravitreal therapies. The study involved collection
of data retrospectively from case notes and OCT scans
performed as part of patients’ standard care pathways at
each institution, approval by Ethics Committee was not
required according to the institutional review policies at
each site. Case notes review was performed and data
were collected at baseline, which was at the time of fluo-
cinolone implant and at the visit nearest to the 3 month
time-point of follow-up. At the baseline time-point, data
were collected on demographics, visual acuity (treated
and fellow eyes), OCT parameters, IOP, IOP lowering
medication use, presence of co-existing ocular pathology
and prior laser for DMO and DR or intravitreal therapy
and duration of DMO. At the 3 month time-point, data
were collected on visual acuity (treated eyes), IOP, IOP
lowering medication use and OCT parameters. Snellen
visual acuity was converted using a standard estimation
method so that all acuity data was presented in terms of
number of ETDRS letters. The type of conversion
method we used would convert 6/60 to 35 letters and 6/
6 to 85 letters as obtained when an ETDRS acuity is
used at 2 meters for acuity scoring. [12, 13]. Descriptive
statistics were used to present the data to demonstrate
the spectrum of baseline characteristics with particular
emphasis on the types of prior therapies which had been
attempted on these eyes prior to using fluocinolone.
Short term follow-up data was analysed to show the ini-
tial efficacy and occurrences of any serious adverse
events.
Results
A total of 22 patients (14 M:8 F) aged between 42 and
85 years (mean 67.2 years) were included. Nineteen pa-
tients had Type-2 and 3 patients had Type-1 diabetes
mellitus; mean duration of diabetes was 17.9 years
(range: 3–60). All patients had unilateral fluocinolone
implants ie; 11 right and 11 left eyes treated.
Visual acuity conversion for Snellen fraction to ETDRS
was required for five patients. In all other patients, acu-
ity scores were captured directly using ETDRS chart.
Treated eyes had mean baseline visual acuity of 50.7 let-
ters and mean CRT of 631 μm. Twenty two eyes had fo-
veal eversion and 13 eyes had pre-existing vitreo-retinal
interface abnormalities. Majority of eyes had prior laser
of either macular or pan retinal photocoagulation. All 22
eyes had prior intravitreal therapy. Thirteen eyes had
prior ranibizumab or bevacizumab, 3 eyes had both rani-
bizumab and bevacizumab and 6 eyes had prior intravit-
real triamcinolone for DMO. Mean duration of DMO
was 26.2 months (range: 9-47). All patients had a mini-
mum of 8 weeks wash out period after using Anti-VEGF
before having the fluocinolone implant.
Fellow eyes had visual acuities ranging from NPL to
85 letters. In 11 patients, the fellow eye had visual acu-
ities equal to or worse than treated eyes. Baseline char-
acteristics of 22 treated eyes are shown in Table 1. From
these characteristics, it is evident that the eyes that were
selected had moderately low visual acuities, severe
macular thickening, presence of other co-existing path-
ologies such as epiretinal membranes and controlled
glaucoma.
At the 3 month time-point, mean change in BCVA for
all patients was +6.4 ETDRS letters (SD: ±7.2; range: -11
to +25). A gain of >0 letters was seen in 21 eyes
(95.4 %); 0-4 letters in 4 eyes (18.1 %), 5-9 letters in 7
eyes (31.8 %) and ≥10 letters in 6 eyes (27.2 %), CRT
after three months reduced by 148.9 μm (SD: ±240.6;
range: -714 to +385 μm). A total of 18 out of 22 eyes
(81.8 %) showed some reduction in CRT at 3-months.
In the 4 eyes without CRT improvement, the mean
increase in CRT was 134.75 μm (SD: ±169.8; range:
+26 to +385 μm).
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Overall, 15 patients (68.2 %) showed some improve-
ment in both visual acuity and CRT, 3 patients (13.6 %)
showed some visual gain without any reduction in CRT,
another 3 patients (13.6 %) achieved a reduction in CRT
without any corresponding visual gain and 1 patient (4.5 %)
did not show any improvement in visual acuity or CRT.
Of the 5 eyes which had undergone prior vitrectomy,
visual acuity was improved by +7.2 letters (range: 0 to
+14) and CRT reduced by 176.8 (range:-714 to +385).
Four of 5 eyes showed both a reduction in CRT with im-
proved visual acuity but one patient had reduced CRT
(-345) with no gain in visual acuity.
One patient worsened by 11 letters and had increase
in CRT of 385 μm; this particular patient had received
prior treatment with macular laser and four ranibizumab
and one triamcinolone intravitreal injections.
Mean baseline IOP was 16.9 mmHg (SD: ±3.1;
range 10–22 mmHg), with the mean change of
0.3 mmHg (SD: ±3.1; range: -7 to +5 mmHg) at
month 3. No cases with substantial elevation in IOP
were documented in the short follow up period. Of
22 eyes, four eyes, were receiving IOP-lowering drops
(timolol and/or latanoprost) prior to fluocinolone im-
plant. Following implant an additional one eye needed
IOP lowering medication.
Discussion
Our study set out to evaluate two important aspects in
the use of fluocinolone acetonide in the real world clin-
ical setting for treatment of DMO; firstly, the character-
istics of patients selected for treatment by clinicians and
secondly, the early treatment response seen in their
patients.
In terms of selection, we found that fluocinolone im-
plant was used infrequently in patients with DMO. In all
three sites, there were only 22 procedures performed in
three sites in the 8-month period following approval of
fluocinolone by NICE. Given the large number of pa-
tients needing repeated injections of ranibizumab for
DMO at these sites [14], this infrequent use of fluocino-
lone suggests that clinicians had a high threshold for
using fluocinolone for DMO. The majority of patients
did have severe oedema with mean CRT of over 600 μm.
The majority of eyes had prior macular laser and all eyes
had prior intravitreal therapy. This finding supports the
fact that clinicians are following the NICE guidance cri-
terion of unresponsiveness to other available therapy
[10]. Six eyes had prior intravitreal triamcinolone but no
anti-VEGF. This reflects the general acceptability of
switching between corticosteroid agents especially if
prior triamcinolone did not cause uncontrolled glau-
coma [15]. This may be an observation of a growing
trend to use a shorter acting intravitreal corticosteroid
such as triamcinolone as a steroid challenge in these pa-
tients, a trend which has been adopted by the American
Food and Drug Administration (FDA) when fluocino-
lone was approved to be used in DMO [11]. Another cri-
terion stipulated by NICE guidance is that the treated
eyes had to be pseudophakic. In this survey, all treated
eyes were already pseudophakic indicating that clinicians
are following NICE guidance recommendation carefully.
We were also interested to evaluate whether clinicians
were reluctant to use fluocinolone in better seeing eyes.
With 11 out of 22 eyes being the better seeing eye, it
does not appear to be the case that there was any reluc-
tance in the selection behaviour of clinicians to avoid
fluocinolone in better seeing eyes. However the majority
of eyes had foveal eversion on OCT. This may be a fu-
ture additional criterion of severity of oedema that could
be used to select the most justifiable cases for fluocino-
lone therapy. All patients in this study had chronic
DMO of more than 2 years, Authors could not identify
any particular pattern between chronicity of DMO and
early response/failure of this cohort of patients although
admittedly is a short follow up period.
In terms of early outcome, we found promising results
with 18 out of 22 eyes reported to have visual gain and
18 out of 22 eyes with at least a reduction in CRT at
month 3 time-point. Figure 1 shows a dramatic reduc-
tion of CRT from 960 μm to 246 μm 3 months post
Table 1 Baseline parameters of Fluocinolone Acetonide implant
treated eyes
Parameter Value
Visual Acuity (ETDRS letters) Range (2–85), Mean (50.7)
Central Retinal Thickness
(Micrometers)
Range (373–1052) .Mean (631)
Duration of DMO(Months) Range (9-47). Mean (26.2)
Foveal eversion 21
Pseudophakia 22
Eyes with one co-existing pathology ERM(n = 11)
VMT(n = 2)
Glaucoma/Ocular hypertension
(n = 4)
NVD n = 1
NVE n = 1
Eyes with >1 co-existing pathologies 3
Eyes on IOP lowering drugs 4
Eyes with prior macular laser only 15
Eyes with prior vitrectomy for
DMO/ERM
1
Eyes with prior intravitreal therapy Ranibizumab only– n = 11
Bevacizumab only n = 2
Rani and Beva n = 3
Triamcinolone n = 6
Eyes with prior PRP 9
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fluocinolone. Given the majority of patients had prior in-
jections of ranibizumab or bevacizumab in this study,
this highlights the additional value that can be gained by
switching from anti-VEGF to intravitreal fluocinolone in
unresponsive cases. This also serves as new evidence for
switching from ranibizumab to fluocinolone as some pa-
tients in the FAME trial had rescue bevacizumab but not
ranibizumab and there have been no published series to
our knowledge of visual outcome when switching from
ranibizumab to fluocinolone. In one case report of a sin-
gle patient, with longstanding DMO which was unre-
sponsive to ranibizumab, Bertelmann and Shulze
reported reduction in oedema and gain in visual acuity
following a switch from ranibizumab to fluocinolone im-
plant [16]. The three month follow-up period is admit-
tedly too short for evaluating the risk of IOP rise. In this
study, only one patient required commencement of IOP
lowering medication at month 3 time-point. Based on
available FAME data on IOP response, it is likely that
more patients will subsequently develop elevated IOP.
There were limitations in the design of this real world
study. The selection of patients for therapy is a complex
process involving careful explanation and the confidence
expressed by the treating clinician at counselling and a
final decision made with the patient preference. It was
possible that many other patients who were eligible for
therapy but declined due to the risk factors involved.
We could not capture those patients who declined treat-
ment with our retrospective design and this study may
represent the highest threshold for using fluocinolone at
this early stage of implementing NICE guidance. We also
captured basic baseline data on patient selection. We
were unable in the scope of this study to capture the
timescale and progression of DMO in these patients. We
recognise that other factors, including the recent wors-
ening of oedema or visual acuity and the frequency of
previous visits do have an impact on tendency to use
fluocinolone and these factors were not be captured uni-
formly in this retrospective design.
The strength of this study was the accuracy of the rep-
resentation of those patients who were treated with fluo-
cinolone. The sites selected were medium sized district
general hospital settings as well as large teaching hos-
pital centres which enables translation of our results to
the majority of hospital eye departments. The inclusion
of all consecutively treated patients in an 8-month
period ensured a representative cohort of patients for
reporting of a potentially wide spectrum of selection cri-
teria used or variable response to treatment.
Conclusion
Numerous review articles have been published mention-
ing fluocinolone therapy for DMO but there is a paucity
of published data on use of fluocinolone 0.2 μg/day or
iluvien® outside the experience of the FAME trial [8, 17].
We are also unaware of any previously published case
series describing the experience of switching from rani-
bizumab to fluocinolone. This study can hope to serve
this small gap in our evidence base and also be of value
for designing selection and follow-up protocols for treat-
ment of patients with the fluocinolone implant.
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Fig. 1 a Spectral Domain OCT at baseline showing extensive intraretinal fluid with foveal eversion. b Spectral Domain OCT at three months
showing significant resolution of intraretinal fluid and the re-formation of the foveal dip
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